Litcius/Paper detail

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)

Eric F. Morand, Edward M Vital, Michelle Petri, Ronald van Vollenhoven, Daniel J. Wallace, Marta Mosca, Richard Furie, Maria Silk, Christina Dickson, Gabriella Meszaros, Bochao Jia, Brenda Crowe, Inmaculada de la Torre, Thomas Dörner

2023The Lancet152 citationsDOIOpen Access PDF

Topics & Concepts

MedicinePlaceboRheumatoid arthritisClinical endpointInternal medicinePopulationLupus erythematosusSystemic lupus erythematosusClinical trialImmunologyDiseaseAntibodyEnvironmental healthPathologyAlternative medicineRheumatoid Arthritis Research and TherapiesSystemic Lupus Erythematosus ResearchSpondyloarthritis Studies and Treatments
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I) | Litcius